The real-world data of the trials showed that patients experienced a 90% reduction in adverse effects associated with marijuana use in comparison with other methods such as oil, smoking, and vaping.
Bedrocan highlights SyqeAir’s TGA Approval in Australia
An article by Bedrocan about Syqe® receiving the Therapeutic Goods Administration (TGA) approval for the SyqeAir inhaler in Australia. This significant regulatory milestone is a step forward in the global expansion of our treatment.